How will the treatment landscape for CTCL change in the coming years?

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Chalid Assaf, MD, PhD, of Helios Klinikum Krefeld, Krefeld, Germany, discusses how the overall treatment landscape for cutaneous T-cell lymphoma (CTCL) will change in the coming years. Not only is there progress in the development of topical treatments for early stage CTCL, but Prof. Assaf also highlights the progress made in treatments for advanced stage CTCL. These treatments include recent antibodies approaches targeting CD30 and CCR4, which have shown promising response rates and improved the quality of life of patients.